Skip to main content
OpenTrials
Completed

NCT Number: NCT01578122

Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome

Post thrombotic syndrome (PTS) is a frequent and burdensome complication of proximal deep-vein thrombosis.Therapeutic options for PTS are limited and mainly rely on its prevention. Therapeutic trials evidenced that elastic compression stockings (ECS) applying 30-40mmHg of pressure at the ankle reduced the rate of PTS by 50%. Although ECS are unlikely to cause harm, in clinical practice, compliance to this treatment appears to be low as ECS may be difficult to apply and to wear.

ECS with a lighter compression strength (20-30mmHg) might be easier to apply and be more comfortable. This could favor a better compliance.

CELEST is a randomized, multicentre, double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Deep Vein Thrombosis Behavior Cardiovascular Diseases Embolism and Thrombosis Health Behavior Patient Acceptance of Health Care Patient Compliance Post-thrombotic Syndrome Postthrombotic Syndrome Thrombosis Treatment Adherence and Compliance Vascular Diseases Venous Insufficiency Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cabinet, Lyon, Rhônes Alpes, France

Loading trial locations.

About this study

CELEST trial is a controlled, randomized, multicentre, non-inferiority double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle. Patients with a first acute symptomatic proximal DVT will be randomized to wear for two years either ECS applying 25mmHg of targeted pressure at the ankle or ECS applying 35mmHg of targeted pressure at the ankle. All patients will be prescribed anticoagulants for at least three months. The primary outcome will be the rate of PTS assessed with the Villalta scale in both arms of the study during the 2 years study period. Rate of compliance,severity of PTS and quality of life in both groups will constitute the main secondary outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient (male/female) at least 18 years old
  • Patient presenting with an initial episode of proximal deep vein thrombosis (DVT) confirmed by an additional examination (echo-Doppler scan) taken no more than 8 days previously :

the proximal character defined by a DVT from the collecting trunk extending from the tibial-peroneal trunk to the inferior vena cava inclusive the unilateral character concerns only the proximal part. Patients with a distal DVT on the contralateral member the day of diagnosis can be included The notion of initial episode concerns only the proximal part. Patients with a preceding DVT limited to distal part can be included

  • with no trophic disorders at baseline (CEAP class 4, 5 or 6 excluded)
  • with or without pulmonary embolism
  • Patient capable of benefiting from anticoagulant therapy of at least 3 months duration
  • Available to participate in a clinical trial with a 24-month follow-up period and for which a delivery of study products may be possible throughout its participation (delivery possible only in Metropolitan France)
  • Life expectancy greater than 24 months
  • Volunteer to take part in the study, having signed the consent form after receiving sufficient information and the information leaflet
  • Person affiliated to social security or the recipient of a similar scheme.

non inclusion criteria

  • Patients with at least one of these contraindications to compression treatment:
  • phlegmasia cerulea dolens,
  • septic thrombosis,
  • product intolerance, allergic reaction to one of the components
  • Arteritis obliterans stage III and IV of the lower limbs (IPS<0.6),
  • Micro-angiopathy, advanced diabetes,
  • Decompensated heart failure,
  • Skin infections: anti-infective treatment must precede compression therapy,
  • Weeping skin diseases of the leg.
  • Compression treatment technically impossible during the study
  • Patients presenting with bilateral venous thrombosis of the lower limbs.
  • Patient having received fibrinolytic treatment, mechanical thrombo-aspiration or venous repermeation surgery for venous thrombosis justifying inclusion
  • Patients having undergone mechanical interruption of the inferior vena cava.
  • Patients for whom long-term elastic compression for the treatment of lymphatic venous insufficiency (patients with lymphoedema), for instance, is indicated prior to DVT. Patients with elastic compression for primary thromboprophylaxis of thromboembolic disease (TED) are eligible.
  • Patients presenting with oedema unrelated to venous insufficiency or in whom oedema is likely to develop within 2 years.
  • Patients receiving diuretic treatment for more than 3 months due to heart failure.
  • Pregnant women
  • Person deprived of liberty by a legal or administrative decision, person under legal protection.
  • Patient currently participating in a clinical trial or having taken part in a clinical trial in the month preceding inclusion
  • Patient presenting with a history of mental or psychiatric illness or any other factor restricting his/her ability to participate in an informed manner and in compliance with the protocol

Treatment and study plan

25mmHg ECS

Device

Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.

Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).

Other names: ACTYS 25® for women, LEGGER 25® for men

35 mmHg ECS

Device

Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).

Other names: ACTYS 35® for women, LEGGER 35® for men

Primary outcomes

  1. To show that elastic compression with ankle pressure targeted at 25 mm Hg is not inferior in preventing the onset of clinical post-thrombotic syndrome to a target ankle pressure of 35 mm Hg (recommended pressure being greater than 30 mm Hg)

    Time frame: 24 months

    cumulative incidence 24 months after inclusion of PTS apparition defined by the Villalta score > or equal to 5. A visual guide will be given to investigators to assist them and standardize PTS evaluation. Investigators will receive a Villalta training during set up visits.

Secondary outcomes

  1. superiority of targeted pressure at 35 mm Hg for compliant patients. Analysis of the primary endpoint per protocol amongst patients responding to the definition of compliance for compression scheduled by randomization

    Time frame: 24 months

    analysis of primary endpoint (cumulative incidence of PTS) amongst patients responding to the definition of observance for compression scheduled by randomization. It means a per protocol analysis. The per protocol analysis defined as follow : patients ideally compliant (see next secondary outcome measure with self declaration of compression carrying superior or equal to 80 % especially)and patients with respect to randomization.

  2. Superiority of 25 mm Hg on the therapeutic compliance criterion

    Time frame: 24 months

    Superiority of 25 mm Hg on the therapeutic compliance criterion at 24 months

    Compliance is defined by 2 conditions :

    • Girerd adapted to elastic compression stocking score adjusted between 0 and 2 (the question 2 will not be taken into account beacause not adapted to the logistics of the study)
    • because of French clinical practices it should be pertinent to take into consideration 2 compliance type :
    • ideal compliance : Self declaration ≥ 80 % (reference PRANDONI)
    • adequate compliance : self declaration between 50 and 79% for (French references Delluc and Optimev study)

  3. superiority of 25 mm Hg for constraints related to compression and chronic venous insufficiency quality of life (CIVIQ)

    Time frame: 3 months, 12 months, 24 months

    CIVIQ quality of life (CIVIQ 20) specific to chronic venous insufficiency at 3 months, 12 months and 24 months and questionnaire about constraints of compression stockings.

  4. non inferiority of 25 mm Hg for the comparative evaluation of the symptomatic effect of short-term compression (pain, sensation of oedema) form baseline to 3 months

    Time frame: 3 months

    Comparison of evolution at short-term (3 months) of venous thrombosis symptoms (pain, oedema feeling). Self assessment by VAS of pain and oedema feeling once a week during 3 months. Assessment by the investigator at inclusion and during visit at 3 months (ankle measurement, clinical signs) will be done also. A statistical analysis will be done as soon as 3 months follow up data will be verified to evaluate symptoms evolution due to deep venous thrombosis.

  5. Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire

    Time frame: 3months, 12 months, 24 months

    Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire (EQ5D)

  6. non inferiority of 25 mm Hg for the intensity of long term chronic venous insufficiency symptoms (12 months and 24 months)

    Time frame: 12 and 24 months

    Long term assessment of evolution and intensity of symptoms (pain, oedema feeling) related to potential post-thrombotic syndrome apparition

    • Monthly self-assessment by VAS for pain and oedema feeling during 24 months. It will be done at the end of each month and will focus on symptoms intensity (last week of the month)
    • An assessment will be done by investigator, in addition of previous criterion, at 12 and 24 months
    • Assessment with the Ginsberg score (interview by the investigator at 12 and 24 months)
    • Comparison of averages on Villalta score (quantitative)

  7. non inferiority of 25 mm Hg for the onset of permanent trophic disorders

    Time frame: 3 months, 12 and 24 months

    CEAP classification evaluated by investigator at 3, 12 and 24 months

  8. non inferiority of 25 mm Hg for the onset of sequalae or post thrombotic residues on an duplex scan at 3 months, 12 and 24 months

    Time frame: 3, 12 and 24 months

    Assessment by duplex scan of deep and superficial veins at 3, 12 and 24 months

    • Assessment by duplex scan of deep reflux (>1s in femoral vein, and/or popliteal vein, tibio peroneal trunck)
    • Assessment by duplex scan of superficial reflux (> 0.5s in great saphenous vein, small saphenous vein, perforating veins)
    • Assessment by echographic score of thickness and location of residual thrombus
    • Assessment by duplex scan of re-canalization of collectors trunks and/or parietal sequalae

  9. testing for the prognostic factors of the onset post thrombotic syndrome and comparison of the onset kinetics of post thrombotic syndrome

    Time frame: 24 months

    variables tested as prognostic factors of post thrombotic syndrome apparition :

    • location of the upper pole of thrombus
    • kinetic of thrombus lysis by duplex scan at 3 months
    • Idiopathic nature of TED
    • Delay of diagnostic of deep venous thrombosis
    • Initial intensity of deep venous thrombosis symptoms
    • Initial evolution of symptoms of deep venous thrombosis between J0 and 3 months
    • Persistence of the symptoms at 3 months
    • Patient's characteristics
    • Kinetic of of Villalta score apparition ≥ 5 by survival curve
    • Kinetic of post thrombotic syndrome apparition by Villalta score

  10. test for key factors in good compliance

    Time frame: 24 months

    Compliance evaluation according to the 2 axes defined on third outcome measure and research of determinants of good compliance by specific questionnaire

  11. Adverse events

    Time frame: 24 months

    description and comparison of the incidence of adverse events including unexpected adverse events, events expected with this type of disease (recurrence of the venous thromboembolic disease, recurrence of deep vein thrombosis, pulmonary embolism, superficial venous thrombosis, venous ulcer) and events possibly related to the study treatment (arterial decompensation passing to Lerich stage III or IV, skin intolerance)

  12. Subgroups analysis of the primary objective and secondary objectives according to the gender stratification criterion and age

    Time frame: 24 months

    Stratification on age (more or less than 65 years-old) for testing the hypothesis by subgroups analysis of the benefit of a better adaptation of compression 25 mm Hg on older subjects, as suggested by S. Khan.

  13. superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome

    Time frame: 24 months

    superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome. Outcome measure identical to primary endpoint

  14. sensitivity analysis of primary endpoint excluding patients with a differential diagnosis can explain a Villalta score ≥ 5

    Time frame: 24 months

    sensitivity analysis of primary endpoint excluding patients with a differential diagnosis which could explain a Villalta score ≥ 5. Outcome measure identical to primary endpoint

Sponsors and collaborators

Lead sponsor

Laboratoires Innothera

Industry

Collaborators

  • Floralis
  • University Hospital, Grenoble

Registry information

Official study title

Evaluation of the Efficacy of Elastic Compression in Preventing Post-thrombotic Syndrome. Randomised Non-inferiority Study for Ankle Pressure Targeted at 25 mm Hg Versus 35 mm Hg

Acronym: CELEST

Important dates

Study start
2012
Primary completion
2019
Study completion
2019
First posted
Apr 16, 2012
Registry last updated
Jan 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.